Figure 7.
Combination treatment of cisplatin significantly enhances the anti‐tumour effect of spautin‐1 in the treatment of melanoma xenograft tumour models. A‐C, A375 melanoma cells (5 × 106 cells/0.1 mL) were xenografted into nude mice. The mice were randomized for intraperitoneal injection of spautin‐1 (40 mg/kg, once every other day) and/or gavage administration of cisplatin (3 mg/kg, once a week) for 14 days. The bodyweight (C) and tumour growth (B) were measured around twice per week. All the tumours were removed, and the weight was measured for each group at the last day (mean values ± SEM, n = 7). Significant differences were evaluated using a one‐way ANOVA. *P < .05 vs control group, # P < .05 vs spautin‐1 group, & P < .05 vs cisplatin group. D, Immunohistochemistry assay assessed Ki67 (upper) and γ‐H2AX (lower). The representative images are shown. E, Proposed working model of spautin‐1 on melanoma cells